NEJM Evidence, volume 1, issue 8

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do-Youn Oh ¹

Aiwu Ruth He ²

Shu-Kui Qin ³

Long Chen ^{4, 5, 6}

Takuji Okusaka ⁷

Arndt Vogel ⁸

J C Kim ⁹

Thatthan Suksombooncharoen ¹⁰

M H Lee ¹¹

Masayuki Kitano ¹²

Howard A Burris ¹³

Mohamed Bouattour ¹⁴

Suebpong Tanasanvimon ¹⁵

Mairéad G McNamara ¹⁶

Renata Zaucha ¹⁷

Antonio Avallone ¹⁸

Benjamin H L Tan ¹⁹

Cundom Juan ²⁰

Choong-kun Lee ²¹

Hidenori Takahashi ²²

Masafumi Ikeda ²³

Jen-Sue Chen ²⁴

Julie Wang ²⁵

Mallory Makowsky ²⁵

Nana Rokutanda ²⁵

Philip He ²⁵

John F. Kurland ²⁵

Gordon Cohen ²⁵

Juan Valle ¹⁶

Show full list: 29 authors

Hide authors affiliations

Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea |

Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC |

Cancer Center of Nanjing, Jinling Hospital, Nanjing, China |

⁴

Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan |

⁵

National Institute of Cancer Research, Tainan, Taiwan |

⁶

National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan |

⁷

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan |

⁸

Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany |

⁹

Division of Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea |

¹⁰

Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand |

¹¹

Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University, Seoul, South Korea |

¹²

Second department of Internal Medicine, Wakayama Medical University, Wakayama, Japan |

¹³

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN |

¹⁴

Department of Liver Cancer Unit, Assistance Publique–Hôpitaux de Paris Hôpital Beaujon, Paris, France |

¹⁵

Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

¹⁶

Division of Cancer Sciences, The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK |

¹⁷

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland |

¹⁸

Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy

¹⁹

Department of Medicine, Washington University School of Medicine, St. Louis, MO |

²⁰

Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina |

²¹

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea |

²²

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan |

²³

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan |

²⁴

Department of Hematology-Oncology, Linkou Chang-Gung Memorial Hospital and Chang-Gung University, Taoyuan City, Taiwan |

²⁵

Astrazeneca, Gaithersburg, MD |

Publication type: Journal Article

Publication date: 2022-06-01

Massachusetts Medical Society

Journal: NEJM Evidence

SJR: —

CiteScore: —

Impact factor: —

ISSN: 27665526

DOI: 10.1056/EVIDoa2200015

Copy DOI

PubMed ID: 38319896

Found

	5 10 15 20 25 30 35 40 45
Cancers	Cancers, 42, 7.51% Cancers 42 publications, 7.51%
Annals of Surgical Oncology	Annals of Surgical Oncology, 18, 3.22% Annals of Surgical Oncology 18 publications, 3.22%
Frontiers in Oncology	Frontiers in Oncology, 15, 2.68% Frontiers in Oncology 15 publications, 2.68%
Frontiers in Immunology	Frontiers in Immunology, 15, 2.68% Frontiers in Immunology 15 publications, 2.68%
Targeted Oncology	Targeted Oncology, 10, 1.79% Targeted Oncology 10 publications, 1.79%
Journal of Hepatology	Journal of Hepatology, 10, 1.79% Journal of Hepatology 10 publications, 1.79%
Zeitschrift fur Gastroenterologie	Zeitschrift fur Gastroenterologie, 10, 1.79% Zeitschrift fur Gastroenterologie 10 publications, 1.79%
Current Oncology	Current Oncology, 9, 1.61% Current Oncology 9 publications, 1.61%
Journal of Clinical Oncology	Journal of Clinical Oncology, 9, 1.61% Journal of Clinical Oncology 9 publications, 1.61%
ESMO Open	ESMO Open, 7, 1.25% ESMO Open 7 publications, 1.25%
Future Oncology	Future Oncology, 7, 1.25% Future Oncology 7 publications, 1.25%
Oncologist	Oncologist, 7, 1.25% Oncologist 7 publications, 1.25%
Japanese Journal of Clinical Oncology	Japanese Journal of Clinical Oncology, 7, 1.25% Japanese Journal of Clinical Oncology 7 publications, 1.25%
Cureus	Cureus, 7, 1.25% Cureus 7 publications, 1.25%
Cancer	Cancer, 6, 1.07% Cancer 6 publications, 1.07%
Immunotherapy	Immunotherapy, 6, 1.07% Immunotherapy 6 publications, 1.07%
Cancer Medicine	Cancer Medicine, 6, 1.07% Cancer Medicine 6 publications, 1.07%
European Journal of Cancer	European Journal of Cancer, 6, 1.07% European Journal of Cancer 6 publications, 1.07%
Hepatology	Hepatology, 6, 1.07% Hepatology 6 publications, 1.07%
BMC Cancer	BMC Cancer, 6, 1.07% BMC Cancer 6 publications, 1.07%
Hepatoma Research	Hepatoma Research, 6, 1.07% Hepatoma Research 6 publications, 1.07%
JCO Precision Oncology	JCO Precision Oncology, 5, 0.89% JCO Precision Oncology 5 publications, 0.89%
The Lancet Gastroenterology and Hepatology	The Lancet Gastroenterology and Hepatology, 5, 0.89% The Lancet Gastroenterology and Hepatology 5 publications, 0.89%
Clinical Cancer Research	Clinical Cancer Research, 5, 0.89% Clinical Cancer Research 5 publications, 0.89%
Digestive Disease Interventions	Digestive Disease Interventions, 5, 0.89% Digestive Disease Interventions 5 publications, 0.89%
ESMO Gastrointestinal Oncology	ESMO Gastrointestinal Oncology, 5, 0.89% ESMO Gastrointestinal Oncology 5 publications, 0.89%
Expert Review of Anticancer Therapy	Expert Review of Anticancer Therapy, 4, 0.72% Expert Review of Anticancer Therapy 4 publications, 0.72%
Cells	Cells, 4, 0.72% Cells 4 publications, 0.72%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 4, 0.72% International Journal of Molecular Sciences 4 publications, 0.72%
	5 10 15 20 25 30 35 40 45

	20 40 60 80 100 120 140
Springer Nature	Springer Nature, 123, 22% Springer Nature 123 publications, 22%
Elsevier	Elsevier, 109, 19.5% Elsevier 109 publications, 19.5%
MDPI	MDPI, 69, 12.34% MDPI 69 publications, 12.34%
Wiley	Wiley, 38, 6.8% Wiley 38 publications, 6.8%
Taylor & Francis	Taylor & Francis, 34, 6.08% Taylor & Francis 34 publications, 6.08%
Frontiers Media S.A.	Frontiers Media S.A., 34, 6.08% Frontiers Media S.A. 34 publications, 6.08%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 21, 3.76% Georg Thieme Verlag KG 21 publications, 3.76%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 18, 3.22% American Society of Clinical Oncology (ASCO) 18 publications, 3.22%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 13, 2.33% Ovid Technologies (Wolters Kluwer Health) 13 publications, 2.33%
Oxford University Press	Oxford University Press, 13, 2.33% Oxford University Press 13 publications, 2.33%
SAGE	SAGE, 10, 1.79% SAGE 10 publications, 1.79%
BMJ	BMJ, 8, 1.43% BMJ 8 publications, 1.43%
OAE Publishing Inc.	OAE Publishing Inc., 7, 1.25% OAE Publishing Inc. 7 publications, 1.25%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 6, 1.07% American Association for Cancer Research (AACR) 6 publications, 1.07%
Baishideng Publishing Group	Baishideng Publishing Group, 5, 0.89% Baishideng Publishing Group 5 publications, 0.89%
Japanese Society of Internal Medicine	Japanese Society of Internal Medicine, 4, 0.72% Japanese Society of Internal Medicine 4 publications, 0.72%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 4, 0.72% Cold Spring Harbor Laboratory 4 publications, 0.72%
S. Karger AG	S. Karger AG, 4, 0.72% S. Karger AG 4 publications, 0.72%
Research Square Platform LLC	Research Square Platform LLC, 4, 0.72% Research Square Platform LLC 4 publications, 0.72%
American Medical Association (AMA)	American Medical Association (AMA), 3, 0.54% American Medical Association (AMA) 3 publications, 0.54%
Society for Translational Oncology	Society for Translational Oncology, 3, 0.54% Society for Translational Oncology 3 publications, 0.54%
British Institute of Radiology	British Institute of Radiology, 2, 0.36% British Institute of Radiology 2 publications, 0.36%
Walter de Gruyter	Walter de Gruyter, 2, 0.36% Walter de Gruyter 2 publications, 0.36%
AME Publishing Company	AME Publishing Company, 2, 0.36% AME Publishing Company 2 publications, 0.36%
Touch Medical Media LTD.	Touch Medical Media LTD., 2, 0.36% Touch Medical Media LTD. 2 publications, 0.36%
Massachusetts Medical Society	Massachusetts Medical Society, 1, 0.18% Massachusetts Medical Society 1 publication, 0.18%
Ediciones Medicina y Cultura	Ediciones Medicina y Cultura, 1, 0.18% Ediciones Medicina y Cultura 1 publication, 0.18%
Consilium Medicum	Consilium Medicum, 1, 0.18% Consilium Medicum 1 publication, 0.18%
IntechOpen	IntechOpen, 1, 0.18% IntechOpen 1 publication, 0.18%
	20 40 60 80 100 120 140